Orforglipron is an oral, once-daily GLP-1 receptor agonist that, unlike semaglutide or tirzepatide, is a small molecule rather than a peptide, so it does not require injection or the manufacturing complexity peptides need. Developed by Eli Lilly (originally discovered by Chugai Pharmaceutical), it received FDA approval in April 2026 under the brand name Foundayo for weight management and type 2 diabetes. It is not a peptide, and community sourcing built around research-chemical peptide vials does not apply to it in the way it does to injectable GLP-1 drugs.
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Non-peptide small molecule GLP-1 receptor agonist |
| Primary research interest | Oral weight management and type 2 diabetes |
| Highest available evidence | Tier 1 – FDA-approved via large phase 3 trials (ATTAIN-1, ATTAIN-2) |
| Human research available | Yes – phase 3 trials in obesity and type 2 diabetes, plus a maintenance/switch trial |
| Development status | Approved (Foundayo, April 2026); developed by Eli Lilly, originally discovered by Chugai Pharmaceutical |
| Regulatory status | FDA-approved (April 2026); UK-authorized (August 2026) |
| Last reviewed | 2026 |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | Orforglipron |
| Alternative names | Foundayo (brand), LY3502970 (code name), OWL833 (code name) |
| Peptide sequence | Not applicable – orforglipron is a non-peptide small molecule, not an amino acid sequence |
| Molecular formula | C48H48F2N10O5 |
| Molecular weight | 882.97 g/mol |
| CAS Registry Number | 2212020-52-3 |
| PubChem CID | 137319706 |
| Chemical modifications | Not applicable (small molecule, not a modified peptide) |
| Peptide class | Non-peptide, small-molecule GLP-1 receptor partial agonist |
| Primary biological target | GLP-1 receptor |
| Developer or originator | Discovered by Chugai Pharmaceutical; licensed to and developed by Eli Lilly |
| Development status | FDA-approved, April 2026 |
What it is
Orforglipron (development code LY3502970, also known as OWL833) is a non-peptide small molecule that activates the GLP-1 receptor, the same receptor targeted by semaglutide, liraglutide, and tirzepatide, but through a completely different chemical structure. It was originally discovered by Chugai Pharmaceutical and licensed to Eli Lilly in 2018. Because it is a small molecule rather than a peptide, it survives stomach acid well enough to be taken as a standard oral tablet, without the absorption-enhancing formulation semaglutide’s oral version (Rybelsus) requires. The FDA approved it in April 2026 for chronic weight management and type 2 diabetes, and UK authorization followed in August 2026, under the brand name Foundayo.
How does it work?
Plain-English explanation
Orforglipron activates the same GLP-1 receptor that natural GLP-1 hormone, semaglutide, and liraglutide all activate, reducing appetite, slowing stomach emptying, and helping the pancreas release insulin appropriately after meals. The practical difference is that it comes as a tablet swallowed once a day, with no injection, no needle, and (unlike oral semaglutide) no requirement to take it on an empty stomach with a small sip of water and wait 30 minutes before eating.
Technical explanation
Orforglipron is a non-peptide, small-molecule partial agonist at the GLP-1 receptor, biased toward cAMP signaling. Being a small molecule rather than a peptide means it is not degraded by digestive proteases the way an unprotected peptide would be, so it does not need the sodium caprate absorption enhancer that oral semaglutide (Rybelsus) uses to get a fragile peptide past the stomach. Its oral bioavailability and pharmacokinetics are consistent with once-daily dosing without food or water timing restrictions, a meaningful practical difference from Rybelsus.
Potential benefits and research applications
Weight loss in obesity and overweight
What is being investigated: whether an oral, non-peptide GLP-1 agonist can match the weight loss seen with injectable GLP-1 drugs. How the effect might occur: appetite suppression and slowed gastric emptying via GLP-1 receptor activation. Evidence: the phase 3 ATTAIN-1 trial, 3,127 adults with obesity or overweight and a weight-related comorbidity, found 12.4 percent mean weight loss at the 36 mg dose over 72 weeks against 0.9 percent on placebo, with 59.6 percent of the highest-dose group losing 10 percent of body weight or more. Strength: has been shown in a large, published phase 3 trial supporting FDA approval. Limitation: 12.4 percent is below the roughly 15 percent seen with injectable semaglutide (Wegovy) and well below tirzepatide, so orforglipron trades some efficacy for oral convenience rather than exceeding injectable options.
Glycemic control in type 2 diabetes
What is being investigated: HbA1c reduction in adults with type 2 diabetes. How the effect might occur: the same GLP-1 receptor mechanism that improves insulin secretion after meals. Evidence: the phase 3 ATTAIN-2 trial, 559 adults with type 2 diabetes over 40 weeks, showed HbA1c reductions of 1.3 to 1.6 percentage points depending on dose, with more than 65 percent of the highest-dose group reaching a non-diabetic HbA1c range, alongside about 8 percent average weight loss. Strength: has been shown in a published phase 3 trial supporting FDA approval for this indication. Limitation: weight loss in the diabetes trial (about 8 percent) was notably smaller than in the obesity trial (12.4 percent), consistent with the general pattern across this drug class of smaller weight loss in people who have diabetes.
Maintenance of weight loss after switching from an injectable GLP-1 drug
What is being investigated: whether people who lose weight on an injectable incretin drug can maintain that loss after switching to oral orforglipron. How the effect might occur: continued GLP-1 receptor activation, just delivered differently. Evidence: a phase 3b trial (ATTAIN-MAINTAIN) reported people who switched from an injectable GLP-1 or GLP-1/GIP drug to orforglipron largely maintained their weight loss. Strength: has been reported in a phase 3b published trial. Limitation: as a switch-maintenance study, it does not show whether orforglipron alone, started from scratch, would have produced the same original weight loss as the injectable drug used to get there.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Because orforglipron is FDA-approved and dispensed as a prescription tablet under the brand name Foundayo, its dosing is published in its FDA-approved labeling rather than circulating primarily through informal or community channels the way unapproved research peptides do.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| ATTAIN-1, obesity/overweight (approved) | Oral | 6 mg, 12 mg, or 36 mg maintenance (titrated from 1 mg) | Once daily | 72 weeks | Published human clinical trial / FDA label |
| ATTAIN-2, type 2 diabetes (approved) | Oral | Comparable dose range, titrated from 1 mg | Once daily | 40 weeks | Published human clinical trial / FDA label |
Orforglipron is a non-peptide small molecule dispensed as an FDA-approved tablet, so its dosing is published in official labeling rather than circulating primarily through informal or community channels.
Amounts studied in human research
ATTAIN-1 tested three once-daily oral maintenance doses (6 mg, 12 mg, and 36 mg) in adults with obesity or overweight, each reached through a titration schedule starting at 1 mg daily and increasing every 4 weeks: 1 to 3 mg for the 6 mg target, 1 to 3 to 6 mg for the 12 mg target, and 1 to 3 to 6 to 12 to 24 mg for the 36 mg target, over 72 weeks total.
ATTAIN-2 tested orforglipron in adults with type 2 diabetes over 40 weeks using a comparable titration approach, with the highest studied dose producing HbA1c reductions of 1.3 to 1.6 percentage points and about 8 percent weight loss.
Practitioner and community-reported protocols
Not consistently reported. Orforglipron is a small molecule, not a peptide, dispensed as an FDA-approved tablet, so it has not developed the same compounded or vendor-sourced dosing culture that surrounds injectable peptides like semaglutide or tirzepatide.
Side effects, risks, and limitations
Across the ATTAIN trials, the most common adverse events were gastrointestinal (nausea, diarrhea, vomiting, constipation), generally mild to moderate, consistent with the GLP-1 receptor agonist class. Discontinuation rates in ATTAIN-1 (21.9 to 24.4 percent across orforglipron doses) were actually lower than on placebo (29.9 percent), an unusual but reported finding. The highest dose reduced high-sensitivity C-reactive protein by 47.7 percent and improved non-HDL cholesterol, triglycerides, and systolic blood pressure. As a molecule approved only since 2026, long-term outcome and safety data comparable to years of experience with older GLP-1 drugs like liraglutide are not yet available.
Regulatory and developmental status
Orforglipron received FDA approval in April 2026, for chronic weight management and type 2 diabetes in adults, combined with diet and exercise, under the brand name Foundayo. UK authorization followed in August 2026. It is the first oral, non-peptide, small-molecule GLP-1 receptor agonist to reach approval in this drug class.
Frequently asked questions
What is orforglipron?
An FDA-approved, once-daily oral tablet (brand name Foundayo) that activates the GLP-1 receptor for weight management and type 2 diabetes. Unlike semaglutide or tirzepatide, it is a small molecule, not a peptide.
Is orforglipron a peptide?
No. It is a non-peptide small molecule, which is part of why it can be taken as an ordinary swallowed tablet without the special empty-stomach timing that oral semaglutide (Rybelsus) requires.
How does it work?
It activates the GLP-1 receptor, the same target as semaglutide and liraglutide, reducing appetite and slowing digestion, through a chemically unrelated small-molecule structure rather than a peptide hormone mimic.
What dosage has been studied?
Phase 3 trials studied 6 mg, 12 mg, and 36 mg once daily by mouth, each reached through a step-up titration starting at 1 mg over several weeks.
How much weight loss has been shown?
About 12.4 percent mean weight loss at the highest dose over 72 weeks in people with obesity, and about 8 percent weight loss over 40 weeks in people with type 2 diabetes.
Is it approved?
Yes. The FDA approved it in April 2026 under the brand name Foundayo, and UK authorization followed in August 2026.
What side effects have been reported?
Mostly gastrointestinal (nausea, diarrhea, vomiting, constipation), generally mild to moderate, similar to other GLP-1 receptor agonists.
How does it compare to semaglutide or tirzepatide?
Its weight loss (about 12.4 percent at the top dose) is somewhat lower than injectable semaglutide and meaningfully lower than tirzepatide, but it offers a standard oral tablet without injections or the strict empty-stomach dosing rules of oral semaglutide.
What remains unknown?
Long-term cardiovascular outcomes and comparative durability of weight loss against injectable options have not been established with the years of follow-up available for older drugs in this class.
Bottom line
Orforglipron is a genuinely new kind of GLP-1 drug: the first non-peptide, oral, once-daily small molecule in this class to reach FDA approval (April 2026, brand name Foundayo), for both weight management and type 2 diabetes. Its weight-loss numbers (about 12.4 percent at the top dose) are solid but somewhat below the top injectable options, and it has not accumulated the years of real-world and outcomes data that older drugs in the class have. Because it is not a peptide, sourcing and dosing questions common to injectable research peptides do not apply to it; it is dispensed as an ordinary prescription tablet.